So, assuming 2% growth, Gilead is slightly undervalued. In fact, Gilead appears valued for 0% growth. Actually, this may be a ...

The reversal of fortunes for Gilead Sciences' Trodelvy in an advanced form of breast cancer is complete, with an FDA approval unlocking what could be a sizeable new market for the TROP2-targeting ...

In March, Gilead Sciences reported positive results for its TROPiCS-02 study of Trodelvy, but the guarded tone of the announcement led to speculation that the data was not as strong as hoped.

There are several risks that investors should be aware of before investing in Gilead Sciences. The first risk to consider would be in terms of the Trodelvy ongoing expansions as of now.

Gilead Sciences, Inc. (Gilead) is providing supply of Trodelvy. In late May 2024, Debiopharm and MEDSIR announced a collaboration to evaluate the clinical combination of Debio 0123, an oral ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

IDEAYA is the study sponsor and Gilead will provide the supply of Trodelvy to Ideaya. IDE397 monotherapy or in combination with Trodelvy has not been approved by any regulatory agency and the ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...

Your FREE insider update on the biggest news stories and investing trends, delivered midday TheChart of the Day belongs to ...

IDEAYA is the study sponsor and Gilead will provide the supply of Trodelvy to IDEAYA. IDE397 monotherapy or in combination with Trodelvy has not been approved by any regulatory agency and the ...

Oppenheimer raised the firm’s price target on Gilead (GILD) to $132 from $115 and keeps an Outperform rating on the shares. The firm says that ...

Gilead’s Q4 revenue rose 6% to $7.57 billion ... The analyst sees challenges in oncology due to competition affecting Kite and Trodelvy but remains positive on Arcellx Inc.’s ACLX partnered ...